Surgery is a time-honored treatment with low side effects. If a patient’s symptoms come back, then I would consider biologics. Biologics give us another piece in our armamentarium of treatment. —James N. Palmer, MD
Explore This IssueNovember 2019
Shared Decision Making
Will otolaryngologists feel threatened by the emergence of biologics that reduce the number of sinus surgeries? This is a natural response, “but also a completely inappropriate way for us to respond to new treatments and technologies that may benefit our patients,” says Dr. Smith. “We have a potential conflict of interest as sinus surgeons. Our allergy/immunology colleagues have a potential conflict of interest as well. The worst thing we can do is put our patients in the middle of our conflicts of interest.”
Dr. Laidlaw, an allergist, said she works in a multidisciplinary manner with surgeons in her health system, so patients are referred to the right clinician for treatment appropriate for their situation.
Dr. Smith agreed. “This highlights the need for multidisciplinary management of this patient population. None of us has all the tools. We need to work together,” he said. “This issue really pushes the paradigm of multidisciplinary collaboration, and that’s where we should take this, almost like tumor boards in cancer treatment. We can make recommendations to patients as a multidisciplinary group.”
Susan Bernstein is a freelance medical writer based in Georgia.